The management of myelofibrosis: A British Society for Haematology Guideline.

This document is an update of the British Society for Haematology guideline on the management of myelofibrosis. It provides healthcare professionals with clear guidance on the stratified management of primary myelofibrosis, as well as post-polycythemia myelofibrosis and post-essential thrombocythemia myelofibrosis. The guidelines discuss various treatment options, including medications like ruxolitinib, fedratinib, momelotinib, and pacritinib, as well as other therapies such as hydroxycarbamide, pegylated interferons, and anti-platelet agents. The document also covers the management of MF-associated anemia, the use of erythropoiesis-stimulating agents, danazol, immunomodulating drugs, and iron chelation therapy. It provides recommendations for special situations and emphasizes the importance of individualized treatment approaches and patient support. Additionally, the document provides recommendations for pretransplant workup, donor choice, conditioning choice, and post allo-HSCT monitoring for patients considering allogeneic stem cell transplantation. [Extracted from the article]